study of c-erb B-2 oncogene expression in salivary gland neoplasms by in situ hybridisation
Read Online
Share

study of c-erb B-2 oncogene expression in salivary gland neoplasms by in situ hybridisation by Richard Jordan

  • 201 Want to read
  • ·
  • 46 Currently reading

Published by Faculty of Dentistry, University of Toronto] in [Toronto .
Written in English


Book details:

Edition Notes

Thesis (M.Sc.)--Faculty of Dentistry, University of Toronto, 1992.

Statementby Richard Jordan.
ID Numbers
Open LibraryOL18705167M

Download study of c-erb B-2 oncogene expression in salivary gland neoplasms by in situ hybridisation

PDF EPUB FB2 MOBI RTF

In order to analyze the correlation between immunohistochemical positivity for c‐erbB‐2 oncoprotein and prognosis in patients with malignant salivary gland tumors, 59 cases of malignant tumors of the. Mutations of the tumour suppressor p53 were first described for salivary gland adenomas in and later in a pilot study of saliva from breast cancer subjects [24]. Few studies suggest elevated. The pattern of expression of the c-erbB-2 oncoprotein was investigated in whole mount preparations of 11 human fetuses by immunocytochemistry using two polyclonal antibodies, 20N and 21N. c-erbB This oncogene has been shown to be over expressed and/or amplified in primary carcinoma of the breast, ovary, pancreas and salivary glands. This study was conducted to evaluate a possible link between amplification of c-erb B-2 oncoprotein and cartilage invasion in laryngeal carcinoma.

  STUDY DESIGN: In this retrospective study 56 trophoblastic tumors were examined by means of immunocytochemical techniques to stain for the oncogene product for evidence of c-erb B-2 expression. Our 56 cases included original tissue from 20 cases of complete mole that progressed to persistent gestational trophoblastic disease, seven cases of.   HER2 oncogene in Costa Rica is less than 8%. This is the first attempt ever undertaken to estimate the prevalence of HER2-positivity in GC in Costa Rica. Keywords: oncogene, gastric cancer (GC), immunohistochemistry (IHC), fluorescent in situ hybridisation (FISH), HER2. To investigate the effects of fixation on the immunohistochemical demonstration of c-erbB-2 oncoprotein using paraffin wax and cryostat sections; to compare c-erbB-2 expression in non-neoplastic. To evaluate the role of the Ki proliferation antigen and c-erbB-2/neu oncogene expression in the clinical assessment of salivary gland tumors, we followed up 71 patients with minor salivary.

  The study of oncogene expression and function is fundamental for tumour therapy. In an earlier study, it was shown that the C-erbB2 gene was over-expressed in many types of tumours. The previous studies also confirmed that C-erbB2 was over-expressed in salivary gland . Purpose: Previous evaluation of HER2 overexpression in salivary gland cancers indicated an incidence varying between 7 and 56%, with no clear difference among three histologically different subtypes. As part of a Phase II trial of trastuzumab for treatment of incurable salivary gland cancer, we screened tumors for HER2 expression. The study of oncogene expression and function is fundamental for tumour therapy. In an earlier study, it was shown that the C-erbB2 gene was over-expressed in many types of tumours. The previous studies also confirmed that C-erbB2 was over-expressed in salivary gland cystic carcinoma–. Hoon H. Sunwoo, Mavanur R. Suresh, in The Immunoassay Handbook (Fourth Edition), Function. The HER-2/c-erb B-2 protein has a critical role in conveying messages into the cell as a member of the growth factor family, via tyrosine kinase-dependent cascade an activating ligand binds to this protein, it dimerizes by associating with another member of the HER family or with.